News

SARS-CoV-2 Rapid Antigen test now available in markets accepting the CE mark

21.09.2020


Roche announced today that the SARS-CoV-2 Rapid Antigen Test is now available in markets accepting the CE mark.

 

The SARS-CoV-2 Rapid Antigen Test is for use in point of care settings for both symptomatic and asymptomatic people. This can help healthcare professionals identify a SARS-CoV-2 infection in people suspected to carry the virus with results typically ready in 15 minutes. It also serves as a valuable initial screening test for individuals that have been exposed to SARS-CoV-2 infected patients or a high risk environment.

Roche also intends to file for Emergency Use Authorisation (EUA) to the U.S. Food and Drug Administration (FDA).

Example

SARS-CoV-2 Rapid Antigen Test

Reliable, rapid chromatographic immunoassay for the qualitative detection of specific antigens of SARS-CoV-2